Telix Pharmaceuticals Limited
TLXHealthcareNASDAQBiotechnology
Scan Results
Daily timeframeHeadquartered within the healthcare sector, Telix Pharmaceuticals Limited focuses on Biotechnology services and products. Telix Pharmaceuticals Limited, a commercial-stage biopharmaceutical company, focuses on the development and commercialization of therapeutic and diagnostic radiopharmaceuticals. Valued at $3.54B, TLX is a mid-cap name in its sector. The company operates through three segments: Precision Medicine, Therapeutics, and Manufacturing Solutions.
Market Cap
$3.54B
Beta
0.63
P/E (TTM)
—
P/E (Fwd)
45.88
EPS (TTM)
$-0.02
EPS (Fwd)
$0.23
ROE
-1.9%
ROA
1.1%
Cash
$141.9M
Total Debt
$467.1M
Free CF
-$36.7M
52W Change
-35.5%
Annual Financials
Cash vs Debt
The company holds $141.9M in cash, though total debt stands at $467.1M. This level of leverage is common in the industry but worth monitoring as interest rate conditions evolve. The company is burning cash, with free cash flow at -$36.7M. This typically occurs when a company is investing aggressively in growth, but sustained cash burn can strain the balance sheet. ROE of -1.9% points to negative capital efficiency, indicating how much profit the company produces per dollar of shareholder equity. ROA of 1.1% is on the lower side, which is common in asset-heavy industries. Revenue has grown from $108.9M (2022) to $803.8M (2025), reflecting a 638% increase over the period.
TLX's low beta indicates it tends to be less volatile than the broader market, which may suit investors seeking more stable price behavior. The company is burning cash at the operating level, which is not unusual for growth-phase companies but adds risk if it persists. Understanding these risk dimensions helps frame what to watch going forward as conditions evolve for Telix Pharmaceuticals Limited and its sector.